Get started
Corvus Pharmaceuticals, Inc.Corvus Pharmaceuticals, Inc.Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CRVS chart


Full chart

CRVS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪320.64 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.93 USD
Net income (FY)
‪−27.03 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪50.33 M‬
Beta (1Y)
1.77

Employees


Employees (FY)
28
Change (1Y)
−1 −3.45%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−965.32 K‬ USD

About Corvus Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Richard A. Miller
Headquarters
Burlingame
Website
corvuspharma.com
Founded
2014
FIGI
BBG009F0TGH8
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CRVS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CRVS is 4.99 USD — it has decreased by −1.96% in the past 24 hours. Watch Corvus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Corvus Pharmaceuticals, Inc. stocks are traded under the ticker CRVS.
CRVS stock has fallen by −38.17% compared to the previous week, the month change is a −40.17% fall, over the last year Corvus Pharmaceuticals, Inc. has showed a 215.82% increase.
We've gathered analysts' opinions on Corvus Pharmaceuticals, Inc. future price: according to them, CRVS price has a max estimate of 24.00 USD and a min estimate of 12.00 USD. Watch CRVS chart and read a more detailed Corvus Pharmaceuticals, Inc. stock forecast: see what analysts think of Corvus Pharmaceuticals, Inc. and suggest that you do with its stocks.
CRVS reached its all-time high on Mar 28, 2017 with the price of 22.14 USD, and its all-time low was 0.61 USD and was reached on Mar 28, 2023. View more price dynamics on CRVS chart.
See other stocks reaching their highest and lowest prices.
CRVS stock is 12.90% volatile and has beta coefficient of 1.77. Track Corvus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Corvus Pharmaceuticals, Inc. there?
Today Corvus Pharmaceuticals, Inc. has the market capitalization of ‪320.64 M‬, it has decreased by −8.88% over the last week.
Yes, you can track Corvus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Corvus Pharmaceuticals, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
CRVS earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.11 USD resulting in a −445.45% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Corvus Pharmaceuticals, Inc. earnings.
Corvus Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CRVS net income for the last quarter is ‪−40.22 M‬ USD, while the quarter before that showed ‪−4.26 M‬ USD of net income which accounts for −843.62% change. Track more Corvus Pharmaceuticals, Inc. financial stats to get the full picture.
No, CRVS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 28.00 employees. See our rating of the largest employees — is Corvus Pharmaceuticals, Inc. on this list?
Like other stocks, CRVS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Corvus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Corvus Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Corvus Pharmaceuticals, Inc. stock shows the buy signal. See more of Corvus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.